c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo

Akt is a central regulator of cardiomyocyte survival after ischemic injury in vitro and in vivo, but the mechanisms regulating Akt activity in the postischemic cardiomyocyte are not known. Furthermore, although much is known about the detrimental role that the c-Jun N-terminal kinases (JNKs) play in promoting death of cells exposed to various stresses, little is known of the molecular mechanisms by which JNK activation can be protective. We report that JNKs are necessary for the reactivation of Akt after ischemic injury. We identified Thr450 of Akt as a residue that is phosphorylated by JNKs, and the phosphorylation status of Thr450 regulates reactivation of Akt after hypoxia, apparently by priming Akt for subsequent phosphorylation by 3-phosphoinositide–dependent protein kinase. The reduction in Akt activity that is induced by JNK inhibition may have significant biological consequences, as we find that JNKs, acting via Akt, are critical determinants of survival in posthypoxic cardiomyocytes in culture. Furthermore, in contrast to selective p38–mitogen-activated protein kinase inhibition, which was cardioprotective in vivo, concurrent inhibition of both JNKs and p38–mitogen-activated protein kinases increased ischemia/reperfusion injury in the heart of the intact rat. These studies demonstrate that reactivation of Akt after resolution of hypoxia and ischemia is regulated by JNKs and suggest that this is likely a central mechanism of the myocyte protective effect of JNKs.

[1]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[2]  K. Webster,et al.  Mitochondrial signals initiate the activation of c‐Jun N‐terminal kinase (JNK) by hypoxia‐reoxygenation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Fuminori Tsuruta,et al.  JNK promotes Bax translocation to mitochondria through phosphorylation of 14‐3‐3 proteins , 2004, The EMBO journal.

[4]  P. Doevendans,et al.  Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in Vivo* , 2004, Journal of Biological Chemistry.

[5]  P. Rakic,et al.  A critical role of neural-specific JNK3 for ischemic apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Vercelli,et al.  A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia , 2003, Nature Medicine.

[7]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[8]  R. Liao,et al.  Deletion of cytosolic phospholipase A2 promotes striated muscle growth , 2003, Nature Medicine.

[9]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[10]  R. Lauro,et al.  Characterization of apoptosis signal transduction pathways in HL‐5 cardiomyocytes exposed to ischemia/reperfusion oxidative stress model , 2003, Journal of cellular physiology.

[11]  U. Tatu,et al.  Stress protein flux during recovery from simulated ischemia: Induced heat shock protein 70 confers cytoprotection by suppressing JNK activation and inhibiting apoptotic cell death , 2003, Proteomics.

[12]  J. Woodgett,et al.  Stabilization of β-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Woodgett,et al.  Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B , 2002, Molecular and Cellular Biology.

[14]  S. Vatner,et al.  The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. , 2002, The Journal of clinical investigation.

[15]  P. Kang,et al.  Direct Activation of Mitochondrial Apoptosis Machinery by c-Jun N-terminal Kinase in Adult Cardiac Myocytes* , 2002, The Journal of Biological Chemistry.

[16]  F. Gao,et al.  p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. , 2002, Cardiovascular research.

[17]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Hajjar,et al.  Akt Activation Preserves Cardiac Function and Prevents Injury After Transient Cardiac Ischemia In Vivo , 2001, Circulation.

[19]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[20]  B. Monia,et al.  Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. , 2001, Molecular pharmacology.

[21]  S. Kassis,et al.  Inhibition of p38 mitogen‐activated protein kinase provides neuroprotection in cerebral focal ischemia , 2001, Medicinal research reviews.

[22]  K. Webster,et al.  Cytoprotection by Jun Kinase During Nitric Oxide–Induced Cardiac Myocyte Apoptosis , 2001, Circulation research.

[23]  J. Woodgett,et al.  Glycogen Synthase Kinase-3β Is a Negative Regulator of Cardiomyocyte Hypertrophy , 2000, The Journal of cell biology.

[24]  D. Bar-Sagi,et al.  Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. , 2000, Science.

[25]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[26]  E. Chan,et al.  MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Gottlieb,et al.  Activation of the JNK pathway is important for cardiomyocyte death in response to simulated ischemia , 1999, Cell Death and Differentiation.

[28]  T. Yue,et al.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.

[29]  K. Wilson,et al.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.

[30]  R. Hajjar,et al.  Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. , 1998, The Journal of clinical investigation.

[31]  A. Clerk,et al.  "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. , 1998, Circulation research.

[32]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[33]  J Ross,et al.  Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.

[34]  E. A. O'neill,et al.  Kinetic mechanism for p38 MAP kinase. , 1997, Biochemistry.

[35]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[36]  L. Zon,et al.  Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun , 1994, Nature.

[37]  J. Woodgett,et al.  The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. , 1994, The Journal of biological chemistry.

[38]  J. Avruch,et al.  Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase-kinase. , 1993, The Journal of biological chemistry.

[39]  John C. Lee,et al.  Inhibition of p 38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion , 1999 .